Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 2

Status

Recruiting 2Completed 2Not yet recruiting 1

Sponsor Class

OTHER 4NIH 1

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 5Other hematologic neoplasm 5

Conditions

Multiple Myeloma 186Lymphoma, Large B-Cell, Diffuse 41Leukemia, Lymphocytic, Chronic, B-Cell 41Recurrence 28Neoplasms, Plasma Cell 27Lymphoma 25Lymphoma, Mantle-Cell 23Lymphoma, Follicular 23Leukemia 20Lymphoma, B-Cell, Marginal Zone 15Lymphoma, Non-Hodgkin 14Leukemia, Myeloid, Acute 13Smoldering Multiple Myeloma 9Myelodysplastic Syndromes 9Lymphoma, T-Cell, Peripheral 7Lymphoma, B-Cell 7Waldenstrom Macroglobulinemia 6Neoplasms 6Neoplasm, Residual 6Immunoglobulin Light-chain Amyloidosis 6Lymphoma, T-Cell 5Leukemia, Plasma Cell 5Leukemia, Myelomonocytic, Chronic 5Renal Insufficiency 4Prostatic Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, T-Cell, Cutaneous 4Hodgkin Disease 4Hematologic Diseases 4Sezary Syndrome 3

Interventions

Dexamethasone 6fludarabine 5Whole-Body Irradiation 5Mycophenolic Acid 5Melphalan 5Lenalidomide 5Cyclophosphamide 5fludarabine phosphate 4Peripheral Blood Stem Cell Transplantation 4Tacrolimus 3Calcium Dobesilate 3Bortezomib 3dexamethasone acetate 2dexamethasone 21-phosphate 2daratumumab 2auricularum 2Stem Cell Transplantation 2Sirolimus 2Antilymphocyte Serum 2Allopurinol 2pomalidomide 1plerixafor 1pegylated granulocyte colony-stimulating factor 1liposomal doxorubicin 1ixazomib 1isatuximab 1ferric pyrophosphate 1elotuzumab 1carmustine, poliferprosan 20 drug combination 1carfilzomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Leukemia, Plasma Cell × Lenalidomide × Clear all
NCT07605416 2026-05-26

Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial

National Cancer Institute (NCI)

Phase 2 Not yet recruiting
74 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell

NCT05870917 2026-03-02

A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia

Institute of Hematology & Blood Diseases Hospital, China

Phase 2 Recruiting
20 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell

NCT06517017 2025-11-28

UltraFrailMM

University of Utah

Phase 2 Recruiting
40 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma

NCT01729091 2025-05-09

Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma

M.D. Anderson Cancer Center

Phase 2 Completed
72 enrolled 14 charts
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma

NCT01553357 2012-03-14

Lenalidomide and Dexamethasone in Primary Plasma Cell Leukemia

IRCCS Centro di Riferimento Oncologico della Basilicata

Phase 2 Completed
23 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡